Page 3 of 6: studies 41 to 60 of 114, newest first. Back to the addiction overview
August 30, 2024
LSD-assisted therapy may reduce anxiety, but a recent study saw adverse effects like paranoia requiring antipsychotics and overnight monitoring in one participant. Psilocybin-assisted therapy showed promise for alcohol use disorder compared to placebo, but the study also involved extensive psychotherapy which likely contributed to improvements. Psychological risks exist and must be considered...
The Journal of Clinical Psychiatry August 25, 2024 Mark A Frye, Balwinder Singh, Scott Breitinger et al. 2 citations
A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to his subsequent relapse to alcohol use?
Research Square August 23, 2024 Mathias E. Jensen, Dea Siggaard Stenbæk, Catharina Messell et al. 1 citation preprint
Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects a single dose have not been investigated. Aims To investigate the pharmacokinetics, feasibility, safety, and efficacy of single-dose psilocybin therapy in AUD. Methods This...
Annual Review of Psychology August 2, 2024 Keith Humphreys, Daniel Stjepanović, Wayne Hall et al. 18 citations
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit...
Pharmacological Reports August 1, 2024 Maja Owe-Larsson, Katarzyna Kamińska, Barbara Buchalska et al. 11 citations
Abstract Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients and may disturb their everyday activities. The pathogenesis of this disease is still not fully elucidated, but dysfunctions of serotonin-, dopamine- and glutamate-mediated neurotransmission together with early...
British Journal of Clinical Pharmacology July 24, 2024 Eric L Garland
The opioid crisis emerged in part due to the overprescribing of opioid analgesics for chronic pain. Although not the only source of the current epidemic of opioid use disorder (OUD), the prescription of opioids for chronic pain remains one vector for the development of opioid misuse and OUD. However, opioid tapering is not appropriate for all patients, and some patients may need to remain on...
Frontiers in Psychology July 16, 2024 Mariana Lozada, Enara García, Alejandro Chaoul et al.
Health is frequently addressed from a dualistic perspective that separates mind and body. The biomedical paradigm tends to focus on observable and measurable symptoms, focusing on objective indicators of disease and relegating subjective experience to a mere epiphenomenon. Moreover, the medical system tends to assume that experts must solve health issues while patients passively receive...
Research Square July 15, 2024 Cynthia U Price, Kenneth C Pike, Anna Treadway et al. preprint
While effective, medication for opioid use disorder (MOUD) treatment outcomes can be limited by co-occurring polysubstance use, mental health and chronic pain conditions. Interoceptive training may facilitate well-being and support medication treatment for MOUD. This study examined the pre-post effects of the mindfulness-based intervention Mindful Awareness in Body-oriented Therapy (MABT) as an...
Current Psychopharmacologye July 4, 2024 Hussein El Bourji, Aziz Farhat, Zahi Hamdan et al.
Background: Following clinical trials on psilocybin for the treatment of pain, anxiety, and depression in patients with cancer, scientific interest emerged in its use for substance use disorders. Methods: In this review of the literature, we summarize available trials looking at the use of psilocybin in addiction Results: One double-blind, randomized clinical trial looked at the effect of...
Psychoactives July 3, 2024 Rosa María Moret, Sergio Sanz‐gómez, Santiago Gascón et al. 4 citations
Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the present narrative review, the relationship between suicidal behavior (SB) and the use and abuse of common recreational drugs, such as alcohol, cannabis, cocaine, methamphetamine, heroin, nicotine, ketamine, psilocybin, MDMA, and LSD, has been explored....
Journal of Psychoactive Drugs July 3, 2024 Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al. 5 citations
Treating cannabis use disorder remains a significant challenge in the field of addiction medicine. Some recent studies point to psychedelic-assisted psychotherapy as a potential treatment option for substance use disorders. The objective of this study was therefore to explore the impact of naturalistic psychedelic experiences on cannabis use and psychological flexibility. An online...
International Journal of Drug Policy July 1, 2024 Masoomeh Maarefvand, Maziyar Ghiabi
In this essay we want to foreground a question: what happens to 'addiction' when we take seriously cultural scripts informing its trajectories? Can this bring us to unthink addiction as problematic notion and move it onto new paradigms that fit better the now acknowledged fluidity and pluralistic episteme of 'addiction' and more broadly of chronic life conditions? Indeed, 'addiction' has become...
Humanities and Meditation Research Institute June 30, 2024 Bo-Mi Lee
This study applied a systematic literature review method to examine studies of mindfulness meditative approaches or interventions for addiction, and to derive implications for the use of meditation for addiction intervention. To this end, until April 2024, a total of six papers were selected and analyzed, including the research foundation registration(candidate) paper among domestic studies,...
International Journal of Molecular Sciences June 20, 2024 Hana Shafique, Julie C Demers, Julia Biesiada et al. 29 citations
NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative diseases, epilepsy, traumatic brain injury, substance abuse disorder (SUD), and major depressive disorder (MDD). (S)-ketamine was the first of a novel class of antidepressants, rapid-acting antidepressants, to be approved for medical use. The stereoisomer, (R)-ketamine...
Cannabis and Cannabinoid Research June 17, 2024 Madeline K Stanger, Harmony O Soffer, Angela D Bryan et al. 1 citation
Introduction: In Colorado, both cannabis and psilocybin are legal and becoming more commonly used. However, there is almost no research detailing the public health concerns regarding negative outcomes (e.g., dependence) of cannabis and psilocybin co-use and motives that may perpetuate these negative outcomes (e.g., coping, boredom). Methods: Using data from a larger observational study on...
Psychedelics June 14, 2024 N. Garel
Dr Nicolas Garel is an Assistant Professor in the Department of Psychiatry and Addictology at the University of Montreal and a junior investigator at the Research Center of the Centre Hospitalier de l'Université de Montréal. Dr Garel did his psychiatry residency at McGill University before completing the Clinician-Investigator Program and a Master's degree at McGill University, studying the...
Frontiers in Psychiatry June 11, 2024 Sandra Szafoni, Piotr Gręblowski, Klaudia Grabowska et al. 12 citations
Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As a result, several studies are currently being conducted to find effective alternatives to traditional therapies. One of these alternatives is psilocybin, a psychedelic substance that has been tested in clinical trials as an adjunct to psychotherapy. These studies focus on patients with major...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal June 10, 2024 Linda Nguyen, Sona Regonda, Adam Gaisinsky
Introduction: Psilocybin is a naturally occurring tryptamine derivative psychedelic compound potently produced by fungi members of the genus Psilocybe. Previous literature has highlighted psilocybin as a serotonin 2A receptor agonist with striking effects on neural plasticity and cognition. Recent studies explore the usage of psilocybin in addressing addictive behaviours and substance abuse....
Delaware journal of public health June 1, 2024 Asim Trimzi, Morgan Campbell
Little is known about the association between psychedelic use and substance abuse in the general population. We present a case of an award winning musician with an extensive history of hallucinogen use during his early life and how this impacted his overall wellbeing and opioid experience.
European Neuropsychopharmacology June 1, 2024 Amelie Zacher, Josua Zimmermann, David M. Cole et al. 10 citations
Methamphetamine (METH, "Crystal Meth") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") share structural-chemical similarities but have distinct psychotropic profiles due to specific neurochemical actions. Previous research has suggested that their impact on social cognitive functions and social behaviour may differ significantly, however, direct comparisons of METH and MDMA users...